ERBB2 and breast cancer: The subtype of ER-poor and HER2-positive breast cancer treated with neoadjuvant PCrbH showed the highest pNNR (79.6% in group-A and 87.9% in group-B) and the least residual (≥4 nodes) involvement (1.9% in group-A and 3% in group-B).